Cover Image
市場調查報告書

H1N1感染疾病:開發平台分析

H1N1 Infection - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 219730
出版日期 內容資訊 英文 203 Pages
訂單完成後即時交付
價格
Back to Top
H1N1感染疾病:開發平台分析 H1N1 Infection - Pipeline Review, H1 2016
出版日期: 2016年04月20日 內容資訊: 英文 203 Pages
簡介

H1N1流感亦被稱之為豬流感,是新種人類的流行性感冒。由傳染性病毒所引起。H1N1流感會感染鼻子的呼吸道、喉、肺。H1N1流感可藉由患者的咳嗽飛沫傳染。常見的症狀有咳嗽、發熱、喉嚨的疼痛、鼻塞和鼻涕、身體的疼痛、頭痛、倦怠感等。主要的治療方法有藥物療法(抗病毒藥物)。

本報告提供H1N1感染疾病的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

H1N1感染疾病概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Adamas Pharmaceuticals, Inc.
  • Akshaya Bio Inc.
  • Altimmune, Inc.
  • Antigen Express, Inc.
  • Beijing Minhai Biotechnology Co., Ltd
  • CEL-SCI Corporation
  • Cilian AG
  • Crucell N.V.
  • CSL Limited
  • EpiVax, Inc.
  • Etubics Corporation
  • Gemmus Pharma Inc.
  • iBio, Inc.
  • ILiAD Biotechnologies, LLC
  • Inovio Pharmaceuticals, Inc.
  • Kineta, Inc.
  • Kyowa Hakko Kirin
  • Medicago Inc.
  • Microbiotix, Inc.
  • Mucosis B.V.
  • NanoViricides, Inc.
  • NewLink Genetics Corporation
  • Onxeo SA
  • OPKO Health, Inc.
  • PDS Biotechnology Corporation
  • REPLICor Inc.
  • Sarepta Therapeutics, Inc.
  • Sirnaomics, Inc.
  • TaiMed Biologics Inc.
  • 武田藥品工業
  • TechnoVax, Inc.
  • Touchlight Genetics Limited
  • United Therapeutics Corporation
  • Vaxart, Inc.
  • Visterra, Inc.

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ADS-324
  • AEA-35p
  • Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza
  • Aspidasept
  • BA-032
  • C-05
  • CiFlu
  • CR-9114
  • CYM-5442
  • diridavumab
  • EP-67
  • Fludase
  • FVH-1
  • Gamma-Flu
  • GP-1001
  • GP-1681
  • GREFLU/CAL
  • H1N1 A/Aichi/2/68 vaccine
  • Human Antibody Based Vaccines
  • Influ-nRNA
  • influenza (strain H5N1, H1N1) vaccine
  • influenza A/California/04/09 (H1N1) vaccine
  • influenza H1N1 vaccine
  • influenza strain A/H1N1 vaccine
  • influenza strain H1N1 (monovalent) vaccine
  • influenza strain H1N1 (mutivalent) vaccine
  • influenza strain H1N1 vaccine
  • influenza strain H1N1 vaccine
  • influenza strains A/H1N1 + A/H3N2 + B (trivalent) vaccine
  • influenza strains A/H1N1 + A/H3N2 + B (trivalent) vaccine
  • influenza strains A/H1N1 + A/H3N2 + B (trivalent, split virion) vaccine
  • influenza Strains H1N1, H3N2, influenza B (quadrivalent) virus like particle vaccine
  • influenza A vaccine
  • influenza vaccine
  • influenza vaccine
  • influenza vaccine
  • LEAPS-H1N1-DC
  • MBX-2329
  • MBX-2546
  • Monoclonal Antibody for Influenza A Infections
  • NVINF-1
  • NVINF-2
  • PDS-0102
  • pertussis strain BPZE1 vaccine
  • PNSIA-28
  • PNSIA-49
  • radavirsen
  • REP-9
  • RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection
  • seasonal influenza vaccine
  • Small Molecule to Agonize IRF-3 for Viral Infections
  • Small Molecules for RSV and Influenza A Infections
  • Small Molecules to Block M2 Channel for Influenza Infections
  • STP-702
  • Synthetic Peptides for Influenza, HSV and HIV Infections
  • TMB-571
  • TVX-002
  • Vaccine to Target TLR2 for Infectious Disease
  • VH-244
  • VIS-410
  • VXAA-1.1
  • Z-3G1

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7819IDB

Summary

Global Markets Direct's, 'H1N1 Infection - Pipeline Review, H1 2016', provides an overview of the H1N1 Infection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for H1N1 Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H1N1 Infection and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of H1N1 Infection
  • The report reviews pipeline therapeutics for H1N1 Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved H1N1 Infection therapeutics and enlists all their major and minor projects
  • The report assesses H1N1 Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for H1N1 Infection

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for H1N1 Infection
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding H1N1 Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • H1N1 Infection Overview
  • Therapeutics Development
    • Pipeline Products for H1N1 Infection - Overview
    • Pipeline Products for H1N1 Infection - Comparative Analysis
  • H1N1 Infection - Therapeutics under Development by Companies
  • H1N1 Infection - Therapeutics under Investigation by Universities/Institutes
  • H1N1 Infection - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • H1N1 Infection - Products under Development by Companies
  • H1N1 Infection - Products under Investigation by Universities/Institutes
  • H1N1 Infection - Companies Involved in Therapeutics Development
    • Adamas Pharmaceuticals, Inc.
    • Akshaya Bio Inc.
    • Altimmune, Inc.
    • Antigen Express, Inc.
    • Beijing Minhai Biotechnology Co., Ltd
    • CEL-SCI Corporation
    • Cilian AG
    • CSL Limited
    • EpiVax, Inc.
    • Etubics Corporation
    • Gemmus Pharma Inc.
    • iBio, Inc.
    • ILiAD Biotechnologies, LLC
    • Inovio Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Kineta, Inc.
    • Kyowa Hakko Kirin Co., Ltd.
    • Medicago Inc.
    • MedImmune, LLC
    • Microbiotix, Inc.
    • Mucosis B.V.
    • NanoViricides, Inc.
    • NewLink Genetics Corporation
    • Novavax, Inc.
    • OPKO Health, Inc.
    • PeptiDream Inc.
    • Sarepta Therapeutics, Inc.
    • Sirnaomics, Inc.
    • Takeda Pharmaceutical Company Limited
    • TechnoVax, Inc.
    • Theraclone Sciences, Inc.
    • Touchlight Genetics Limited
    • United Therapeutics Corporation
    • Vaxart, Inc.
    • Vironova AB
    • Visterra, Inc.
    • Zydus Cadila Healthcare Limited
  • H1N1 Infection - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-06 - Drug Profile
    • ADS-324 - Drug Profile
    • AEA-35p - Drug Profile
    • Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza - Drug Profile
    • Aspidasept - Drug Profile
    • C-05 - Drug Profile
    • CiFlu - Drug Profile
    • CR-9114 - Drug Profile
    • diridavumab - Drug Profile
    • Fludase - Drug Profile
    • FluGEM - Drug Profile
    • FVH-1 - Drug Profile
    • Gamma-Flu - Drug Profile
    • GP-1001 - Drug Profile
    • GP-1681 - Drug Profile
    • GREFLU/CAL - Drug Profile
    • H1N1 [A/Aichi/2/68] vaccine - Drug Profile
    • HB-36.6 - Drug Profile
    • Human Antibody Based Vaccines - Drug Profile
    • iHA-24 - Drug Profile
    • infectious vaccine - Drug Profile
    • Influ-nRNA - Drug Profile
    • influenza [serotype A] vaccine - Drug Profile
    • influenza [strain A/H1N1] vaccine - Drug Profile
    • influenza [strain A/H1N1] vaccine - Drug Profile
    • influenza [strain A/H1N1] vaccine - Drug Profile
    • influenza [strain H1N1] (monovalent) vaccine - Drug Profile
    • influenza [strain H1N1] (mutivalent) vaccine - Drug Profile
    • influenza [strain H1N1] vaccine - Drug Profile
    • influenza [strain H1N1] vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent, virus like particle) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
    • influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
    • influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile
    • influenza vaccine - Drug Profile
    • influenza vaccine - Drug Profile
    • INO-3510 - Drug Profile
    • JNJ-872 - Drug Profile
    • LEAPS-H1N1-DC - Drug Profile
    • MBX-2329 - Drug Profile
    • MBX-2546 - Drug Profile
    • NEO-8877 - Drug Profile
    • NVINF-1 - Drug Profile
    • NVINF-2 - Drug Profile
    • pertussis [strain BPZE1] vaccine - Drug Profile
    • PNSIA-28 - Drug Profile
    • PNSIA-49 - Drug Profile
    • radavirsen - Drug Profile
    • Recombinant Protein to Target Sialic Acid Receptor for Influenza A Infections - Drug Profile
    • RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection - Drug Profile
    • Small Molecules for RSV and Influenza A Infections - Drug Profile
    • Small Molecules to Agonize IRF-3 for Viral Infections - Drug Profile
    • Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile
    • Small Molecules to Inhibit Influenza A Endonuclease for H1N1 Infections - Drug Profile
    • STP-702 - Drug Profile
    • Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile
    • TCN-032 - Drug Profile
    • TVX-002 - Drug Profile
    • VH-244 - Drug Profile
    • VIS-410 - Drug Profile
    • VNFC-045 - Drug Profile
    • VNFC-051 - Drug Profile
    • VXAA-1.1 - Drug Profile
    • Z-3G1 - Drug Profile
  • H1N1 Infection - Recent Pipeline Updates
  • H1N1 Infection - Dormant Projects
  • H1N1 Infection - Discontinued Products
  • H1N1 Infection - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for H1N1 Infection, H1 2016
  • Number of Products under Development for H1N1 Infection - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016
  • H1N1 Infection - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016
  • H1N1 Infection - Pipeline by Akshaya Bio Inc., H1 2016
  • H1N1 Infection - Pipeline by Altimmune, Inc., H1 2016
  • H1N1 Infection - Pipeline by Antigen Express, Inc., H1 2016
  • H1N1 Infection - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016
  • H1N1 Infection - Pipeline by CEL-SCI Corporation, H1 2016
  • H1N1 Infection - Pipeline by Cilian AG, H1 2016
  • H1N1 Infection - Pipeline by CSL Limited, H1 2016
  • H1N1 Infection - Pipeline by EpiVax, Inc., H1 2016
  • H1N1 Infection - Pipeline by Etubics Corporation, H1 2016
  • H1N1 Infection - Pipeline by Gemmus Pharma Inc., H1 2016
  • H1N1 Infection - Pipeline by iBio, Inc., H1 2016
  • H1N1 Infection - Pipeline by ILiAD Biotechnologies, LLC, H1 2016
  • H1N1 Infection - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • H1N1 Infection - Pipeline by Johnson & Johnson, H1 2016
  • H1N1 Infection - Pipeline by Kineta, Inc., H1 2016
  • H1N1 Infection - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • H1N1 Infection - Pipeline by Medicago Inc., H1 2016
  • H1N1 Infection - Pipeline by MedImmune, LLC, H1 2016
  • H1N1 Infection - Pipeline by Microbiotix, Inc., H1 2016
  • H1N1 Infection - Pipeline by Mucosis B.V., H1 2016
  • H1N1 Infection - Pipeline by NanoViricides, Inc., H1 2016
  • H1N1 Infection - Pipeline by NewLink Genetics Corporation, H1 2016
  • H1N1 Infection - Pipeline by Novavax, Inc., H1 2016
  • H1N1 Infection - Pipeline by OPKO Health, Inc., H1 2016
  • H1N1 Infection - Pipeline by PeptiDream Inc., H1 2016
  • H1N1 Infection - Pipeline by Sarepta Therapeutics, Inc., H1 2016
  • H1N1 Infection - Pipeline by Sirnaomics, Inc., H1 2016
  • H1N1 Infection - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • H1N1 Infection - Pipeline by TechnoVax, Inc., H1 2016
  • H1N1 Infection - Pipeline by Theraclone Sciences, Inc., H1 2016
  • H1N1 Infection - Pipeline by Touchlight Genetics Limited, H1 2016
  • H1N1 Infection - Pipeline by United Therapeutics Corporation, H1 2016
  • H1N1 Infection - Pipeline by Vaxart, Inc., H1 2016
  • H1N1 Infection - Pipeline by Vironova AB, H1 2016
  • H1N1 Infection - Pipeline by Visterra, Inc., H1 2016
  • H1N1 Infection - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • H1N1 Infection Therapeutics - Recent Pipeline Updates, H1 2016
  • H1N1 Infection - Dormant Projects, H1 2016
  • H1N1 Infection - Dormant Projects (Contd..1), H1 2016
  • H1N1 Infection - Dormant Projects (Contd..2), H1 2016
  • H1N1 Infection - Dormant Projects (Contd..3), H1 2016
  • H1N1 Infection - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for H1N1 Infection, H1 2016
  • Number of Products under Development for H1N1 Infection - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top